N/A
N=92
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03328663 ↗Enrolled (actual)
92
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Feasibility of the Intervention (Feasibility Description Below) — 36 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CARE (Other); Standard Transplant Care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Massachusetts General Hospital
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility of the Intervention (Feasibility Description Below) |
36 | — |
| SECONDARY Compare Caregiver Quality of Life (QOL) as Measured by the Caregiver Oncology QOL (CarGOQOL) Questionnaire Between the Study Arms |
81.22; 70.96 | — |
| SECONDARY Compare Caregiving Burden (CRA) Between the Study Arms |
46.95; 55.06 | — |
| SECONDARY Compare Caregiver Anxiety Using Hospital Anxiety and Depression Scale (HADS) Between the Study Arms |
3.62; 7.22 | — |
| SECONDARY Compare Caregiver Self-efficacy Using the Cancer Self-Efficacy Scale-Transplant (CASE-t) Between the Study Arms |
156.20; 147.06 | — |
| SECONDARY Compare Perceived Coping Skills (MOCS) Between the Study Arms |
36.54; 28.02 | — |
Summary
This research study is evaluating the impact of a psychological intervention on the quality of life and mood of caregivers of patients undergoing stem cell transplant.
Eligibility Criteria
Inclusion Criteria
- Adult caregivers (≥18 years) of patients undergoing autologous or allogeneic HCT at MGH, and they must attend the HCT consent visit with the patient.
- A relative or a friend who either lives with the patient or has in-person contact with him or her at least twice per week and is identified as the primary caregiver for transplant.
- Ability to speak English or able to complete questionnaires with minimum assistance of an interpreter.
Exclusion Criteria
- Significant uncontrolled psychiatric or other co-morbid disease, which the primary oncologist believes prohibits the ability to participate in study procedures
Data sourced from ClinicalTrials.gov (NCT03328663). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.